Skip to content
thestock.space

Wockhardt (WOCKPHARMA) had a P/E of 77.2× on 6 Nov 2026, above the industry P/E of 28.7×, and the shares are 20% below their 52-week high. Sales grew 7.8% a year over 3 years; its ROCE of 6.4% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.41× equity. It is a small-cap company with a market cap of ₹31,641 Cr, ranked 19th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 46% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹1,982.00
Day high
₹1,984.60
Day low
₹1,903.10
Prev. close
₹1,989.70
Volume
6.7 L

Health check

1 good · 1 fair · 4 to check
  • ReturnsAhead

    +45.7% over a year, better than 5 of 7 peers.

  • Price tagPricier

    P/E 77.2 vs industry 28.7.

  • GrowthSlow

    Sales +7.8% a year over 3 years.

  • ProfitabilityWeak

    ROCE 6.4% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.41× equity, interest covered 2.1×, Piotroski 8 of 9.

  • Red flags2 to check

    Return on equity is low at 7.8%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹31,641 Cr, #19 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹3,841 Cr · profit ₹410 Cr
Market cap
₹31,641 Cr
Small cap
P/E
77.2
Industry 28.7
Price to book
6.15
Peers 4.99
Dividend yield
0.00%
ROE
7.8%
Peers 14.7%
ROCE
6.4%
Peers 17.9%
Debt to equity
0.41
Debt ₹2,238 Cr
EPS (TTM)
₹25.22
Face value ₹5
OPM (TTM)
19.2%
Net margin 10.7%
Sales growth
+25.3%
Latest quarter vs a year ago
Profit growth
+0.8%
Latest quarter vs a year ago
Price to sales
8.24
EV/EBITDA 44.8

Strengths and risks

Strengths

  • Quarterly sales up 25.3% on a year ago.

Risks to check

  • Return on equity is low at 7.8%.
  • P/E of 77.2 against an industry P/E of 28.7.

Derived automatically from reported figures. Not a recommendation.

About Wockhardt

Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and…

Headquarters
Mumbai
Employees
2,564
Sector
Healthcare
ISIN
INE049B01025
Website
wockhardt.com

Price range

52 weeks

₹1,086.70₹2,422.30

Today

₹1,903.10₹1,984.60
Avg volume (3M)
9.2 L
1-year return
plus 45.7%
From 52-week high
minus 19.6%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
WOCKPHARMAWockhardt1,947.00minus 2.15%31,64177.26.156.4%7.8%19.2%7.8%–0.00%plus 45.7%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Dec 25Mar 26Jun 26Sep 26
738888965929969
637715769741805
101173196188164
13.7%19.5%20.3%20.2%16.9%
−929743520
4860505256
5665535555
−97−1022––
−1096718911673
0.9%9.0%13.2%7.8%–
−905916610679
-5.533.6110.226.554.85

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+7.8%
ROE
7.8%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2,6462,7892,9153,317
–+5.4%+4.5%+13.8%
2,5442,6952,5182,687
10294397630
3.9%3.4%13.6%19.0%
8314555128
292291251208
251223217227
−266−145–−85
−624−420−16238
0.5%−12.4%−256.3%16.4%
−559−463−47213
-38.79-32.05-3.0213.10

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
72778181
3,2823,2824,2724,859
2,1842,3562,0212,233
2,1451,9341,7611,442
7,6837,6498,1358,615
2,4482,3182,2412,302
426443523684
90505534629
4,7194,3834,8375,000
7,6837,6498,1358,615

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
153219−22390
−125−137−783−241
−315334409−54
−287416−39695
−209−216−365−364
−563−38726

Shareholding pattern

Source: NSE filings
49.3%
promoters
  • Promoters49.32%
  • Public50.68%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202649.32%50.68%plus 0.24
30 Jun 202649.08%50.92%0.00
31 Mar 202649.08%50.92%0.00
31 Dec 202549.08%50.92%0.00
30 Sep 202549.08%50.92%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you